Turn Therapeutics Inc. (TTRX) - Form 8-K Summary
Business Context and Reporting Period
Turn Therapeutics Inc., a Delaware corporation and emerging growth company, filed this Current Report on Form 8-K on August 14, 2026. The filing discloses a private placement transaction involving the issuance of common stock to accredited investors.
Key Financial Metrics
This filing reports a specific capital raise event rather than comprehensive financial statements. Key metrics disclosed include:
- Shares Issued: 135,000 shares of common stock.
- Purchase Price: $10.00 per share.
- Aggregate Gross Proceeds: $1.35 million.
- Investor Base: Existing series and seed investors.
The filing does not provide data on revenue, profit, operating cash flow, margins, total debt, or overall liquidity positions.
Material Changes
The primary material change is the increase in outstanding common stock and the infusion of $1.35 million in gross proceeds. The transaction was executed as a private placement under Section 4(a)(2) of the Securities Act of 1933 and Regulation D. Investors were granted registration rights regarding the newly issued shares.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure that the information in Item 7.01 is not deemed "filed" for purposes of Section 18 of the Exchange Act. No unusual items or contingencies were disclosed in this report.
Investor Verification Checklist
- Verify the dilution impact of the 135,000 new shares on existing shareholders.
- Confirm the use of the $1.35 million in proceeds (not specified in this filing).
- Review the terms of the registration rights granted to investors.
- Check subsequent filings for updated cash balance and liquidity status.